Interferon beta in relapsing-remitting multiple sclerosis: An eight years experience in a specialist multiple sclerosis centre

Journal of Neurology

Volumn 252, Issue 7, 2005, Pages 795-800

  Río, Jordi ^a   Tintoré, Mar ^a   Nos, Carlos ^a   Téllez, Nieves ^a   Galán, Ingrid ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Interferon beta; Multiple sclerosis; Observational study

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISABILITY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; DEMOGRAPHY; DISABILITY EVALUATION; DRUG ADMINISTRATION ROUTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 22144447781     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-005-0748-5     Document Type: Article

References (24)

1. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. (1996) Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
3. PRIMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
4. Paty DW, Li DK, for the University of British Columbia MS/MRI Study Group and the IFNβ Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667
5. Simon JH, Jacobs LD, Campion M, et al. for the Multiple Sclerosis Collaborative Research Group (1998) Magnetic Resonance studies of intramuscular interferon β-1a for the relapsing multiple sclerosis. Ann Neurol 43:79-87
6. Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 46:197-206
7. Durelli L, Verdun E, Barbero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
8. Panitch H, Goodin DS, Francis G, et al. EVIDENCE Study Group (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
9. Clanet M, Radue EW, Kappos L, et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517
10. Noseworthy J, O'Brien P, Erickson BJ, Lee D, et al. (1998) The Mayo Clinic Canadian-Cooperative Trial of Sulfasalazine in active multiple sclerosis. Neurology 51:1342-1352
11. Rio J, Nos C, Tintore M, et al. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting MS patients treated with interferon beta. Implications for clinical trials. Ann Neurol 52:400-406
12. Wingerchuk DM, Noseworthy JH (2002) Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 58(8 Suppl 4):S40-S48
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
14. Benson K, Arthur HJ (2000) A comparison of observational studies and randomized controlled trials. N Eng J Med 342:1878-1886
15. Concato J, Shah N, Horowitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887-1892
16. Pocock SJ, Elbourne DR (2000) Randomized trials or observational tribulations? N Engl J Med 342:1907-1909
17. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial (1995) The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45:1277-1285
18. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628-1636
19. Trojano M, Liguori M, Paolicelli D, et al. (2003) Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 9:451-457
20. Waubant E, Vukosic S, Gignoux L, et al. (2003) Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61:184-189
21. Dubois BD, Keenan E, Porter BE, et al. (2003) Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 74:946-949
22. Weinshenker BG, Ebers GC (1987) The natural history of multiple sclerosis. Can J Neurol Sci 14:255-261
23. Goodin DS (2003) Interferons in relapsing remitting multiple sclerosis. Lancet 361:1821
24. Malucchi S, Sala A, Gilli F, et al. (2004) Neutralizing antibodies reduce the efficacy of IFNß during treatment of multiple sclerosis. Neurology 62:2031-2037